Gabapentin may be hazardous in myasthenia gravis

Muscle and Nerve

Volumn 23, Issue 8, 2000, Pages 1204-1208

  Boneva, Neli ^a   Brenner, Talma ^a   Argov, Zohar ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Acetylcholine receptor; Experimental autoimmune myasthenia gravis; Gabapentin; Myasthenia gravis; Repetitive nerve stimulation

Indexed keywords

CHOLINERGIC RECEPTOR ANTIBODY; GABAPENTIN; PYRIDOSTIGMINE;

ADULT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CASE REPORT; CONTROLLED STUDY; FEMALE; HUMAN; MASTICATION; MUSCLE FATIGUE; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; NERVE STIMULATION; NONHUMAN; PRIORITY JOURNAL; RAT;

ACETIC ACIDS; ACTION POTENTIALS; AGED; AMINES; ANIMALS; ANTICONVULSANTS; AUTOANTIBODIES; CHOLINESTERASE INHIBITORS; CYCLOHEXANECARBOXYLIC ACIDS; ELECTRIC STIMULATION; ELECTROPHYSIOLOGY; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MYASTHENIA GRAVIS; PYRIDOSTIGMINE BROMIDE; RATS; RATS, INBRED LEW; RECEPTORS, CHOLINERGIC;

EID: 0033862272     PISSN: 0148639X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-4598(200008)23:8<1204::AID-MUS7>3.0.CO;2-H     Document Type: Article

References (24)

1. Argov Z, Brenner T, Abramsky O. Ampicillin may aggravate clinical and experimental myasthenia gravis. Arch Neurol 1986;43:255-256.
2. Argov Z, Wirguin I. Drugs and the neuromuscular junction: pharmacotherapy and adverse effects in transmission disorders. In: Lisak RP, editor. Handbook of myasthenic syndromes. New York: Marcel Dekker; 1994. p 295-319.
3. Attal N, Brasseur L, Parker F, Chauvin M, Bouhassira D. Effects of gabapentin on the different components of peripheral and central neuropathic pain syndromes: a pilot study. Eur Neurol 1998;40:191-200.
4. Bartosyk GD. Gabapentin and convulsions provoked by excitatory amino acids. Naunyn Schiedebergs Arch Pharmacol 1983;324 (suppl):R24.
5. Beydoun A, Fakhoury T, Nasreddine W, Abou-Khalil B. Conversion to high dose gabapentin monotherapy in patients with medically refractory partial epilepsy. Epilepsia 1998;39:188-193.
6. Brenner T, Abramsky O, Lisak RP, Zweiman B, Tarrab-Hazdai R, Fuchs S. Radioimmunoassay of antibodies to acethylcholine receptor in serum of myasthenic patients. Isr J Med Sci 1978;14:986-987.
7. [3H]gabapentin binding affinity. J Biol Chem 1998;273: 25458-25465.
8. Engel AG, Tsujihata M, Lindstrom JM, Lennon VA. The motor end plate in myasthenia gravis and experimental autoimmune myasthenia gravis. A quantitative ultrastructural study. Ann NY Acad Sci 1976;247:60-79.
9. 2δ subunit of a calcium channel. J Biol Chem 1996;271:5768-5776.
10. [3H]gabapentin to a novel site in rat brain: autoradiographic studies. Eur J Pharmacol 1993;244:303-309.
11. Jones DL, Sorkin LS. Systemic gabapentin and S(+)-3-isobutyl-γ-aminobutyric acid block secondary hyperalgesia. Brain Res 1998;810:93-99.
12. Khan OA. Gabapentin relieves trigeminal neuralgia in multiple sclerosis patients. Neurology 1998;51:611-614.
13. Lennon VA, Lindstrom JM, Seybold ME. Experimental autoimmune myasthenia: a model of myasthenia gravis in rats and guinea pigs. J Exp Med 1975;141:1365-1375.
14. McLean MJ. Gabapentin. Epilepsia 1995;36 (Suppl 2):S73-S86.
15. Meldrum BS. Update of the mechanism of action of antiepileptic drugs. Epilepsia 1996;37 (Suppl 6):S4-S11.
16. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gahapentin for the treatment of postherpetic neuralgia: a randomized trial. JAMA 1998;280:1837-1842.
17. Seybold ME, Lambert EH, Lennon VA, Lindstrom JM. Experimental autoimmune myasthenia: clinical, neurophysiologic, and pharmacological aspects. Ann NY Acad Sci 1976;274: 27.5-282.
18. Singh L, Field MJ, Ferris P, Hunter JC, Oles RJ, Williams RG, Woodruff GN. The antiepileptic agent gabapentin (Neurontin) possesses anxiolytic-like and antinociceptive actions that are reversed by D-serine. Psychopharmacology (Berl) 1996; 127:1-9.
19. Taylor CP, Gee NS, Su TZ, Kocsis JD, Welty DF, Brown JP, Dooley DJ, Boden P, Singh L. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res 1998; 29:233-249.
20. The U.S. Gabapentin Study Group. The long-term safety and efficacy of gabapentin (Neurontin) as add-on therapy in drug resistant partial epilepsy. Epilepsy Res 1994;18:67-73.
21. Watson WP, Robinson E, Little HJ. The novel anticonvulsant, gabapentin, protects against both convulsant and anxiogenic aspect of the ethanol withdrawal syndrome. Neuropharmacology 1997;36:1369-1375.
22. Welty DF, Schielke GP, Vartanian MG, Taylor CP. Gabapentin anticonvulsant action in rats: disequilibrium with peak drug concentration in plasma and brain microdialysate. Epilepsy Res 1993;16:175-181.
23. Wilson EA, Sills GJ, Forrest G, Brodie MJ. High dose gabapentin in refractory partial epilepsy: clinical observation in 50 patients. Epilepsy Res 1998;29:161-166.
24. Wirguin I, Brenner T, Sicsic C, Argov Z. Variable effect of calcium channel blockers on the decremental response in experimental autoimmune myasthenia gravis. Muscle Nerve 1994;17:523-527.